{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:20:55Z","timestamp":1786332055362,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Bayer AG and Janssen Scientific Affairs"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/ehjcvp\/pvy041","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T20:07:59Z","timestamp":1542053279000},"page":"70-79","source":"Crossref","is-referenced-by-count":33,"title":["Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study"],"prefix":"10.1093","volume":"5","author":[{"given":"Pierre","family":"Amarenco","sequence":"first","affiliation":[{"name":"Department of Neurology and Stroke Center, Paris-Diderot-Sorbonne University, 16 rue Henri Huchard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Haas","sequence":"additional","affiliation":[{"name":"Formerly Technical University Munich, Arcisstra\u00dfe 21, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hess","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Bayer AG, M\u00fcllerstra\u00dfe 178, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham and Sandwell & West Birmingham Hospitals NHS Trust, Edgbaston, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambelet","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH & Co KG, Girardetstra\u00dfe 1-5, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bach","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Bayer AG, M\u00fcllerstra\u00dfe 178, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G G","family":"Turpie","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiovascular and Cell Sciences Research Institute, St George\u2019s, Cranmer Terrace, University of London, London, UK"},{"name":"Department of Genetics and Imaging, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B8","author":"Bayer","year":"2018"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/VHRM.S63298","article-title":"XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation","volume":"10","author":"Camm","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B11","year":"2018"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B13","article-title":"XANTUS Investigators. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS","author":"Camm","year":"2018","journal-title":"Europace"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B14","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019031504562195700_pvy041-B15","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/5\/2\/70\/28073984\/pvy041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T08:56:44Z","timestamp":1552640204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/5\/2\/70\/5181122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,11,13]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvy041","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,11,13]]}}}